Anti-angiogenic therapy
AssigneesThromboGenics NV, Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Life Sciences Research Partners VZW
InventorsJean-Marie STASSEN, Peter CARMELIET, Desire COLLEN
Life of this patent
Estimating the term…
Abstract
The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
Claims16
An isolated antibody capable of binding to human P1GF or an antigen-binding fragment of said antibody, wherein said antibody comprises a variable heavy chain sequence of which the sequence of the CDR1, CDR2, and CDR3 region corresponds to the sequence of SEQ ID NO:
- 17, 18, and 19, respectively, and comprises a variable light chain sequence of which the sequence of the CDR1, CDR2, and CDR3 region corresponds to the sequence of SEQ ID NO:
- 20, 21, and 22, respectively.
Dependencies are inferred from the claim text.